On May 14, 2025 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 for EGFR inhibitor ("EGFRi")-associated rash at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) (Press release, Azitra, MAY 14, 2025, View Source [SID1234653053]). ASGCT (Free ASGCT Whitepaper) is being held May 13-17, 2025, in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
Event:
American Society of Gene and Cell Therapy
Location:
New Orleans Ernest N. Morial Convention Center, New Orleans, Louisiana
When:
May 15, 2025; 5:30-7:00PM CT
Title:
A Novel Staphylococcus epidermidis Compound for the Topical Treatment Epidermal
Growth Factor Receptor (EGFR) Inhibitor-Induced Dermal Toxicity
Presenter:
Mary Spellman, MD, Chief Medical Officer
Registration:
"The Annual Meeting of ASGCT (Free ASGCT Whitepaper) is an important conference for researchers and industry leaders who are seeking to develop next-generation cell and gene therapies for patients in need," said Mary Spellman, MD, Chief Medical Officer of Azitra. "We are excited to present supporting evidence for the clinical development of topical ATR04-484 and our Phase 1/2 clinical study design, in anticipation of initiating dosing for the first patient in the coming month."